Obama's Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)

DALLAS, June 16, 2010 - The Healthcare practice at MarketsandMarkets is pleased to announce a new
report titled Obama's Healthcare Reform Bill and its Impact on the U.S.
Healthcare Markets (Pharmaceuticals, Medical devices and Health insurance).

Browse in-depth TOC on Obama's Healthcare Reform Market Report.
Early buyers will receive 10% customization of reports
www.marketsandmarkets.com/Market-Reports/Impact-Obama-Health-US-240.ht
ml

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

Key take aways

    - To describe US healthcare system
    - To identify the need of the health reform in the US
    - To analyze Obama's health reforms and other initiatives in health
      care sector
    - Analyze and discuss the benefits and challenges of Obama's health
      reforms
    - Impact analysis of Obama's health reform on the pharmaceutical,
      biotech and medical devices industry
    - To study the impact of Obama's health reforms on payers,
      providers and beneficiaries & consumers of the US healthcare system
    - Analyze the impact of various provisions of Obama's health reform
    - Economic impact of Obama's health reform

Report description

The US healthcare system ranks 37 among health care systems of about 200
worldwide countries ranked by World Health Organization. US health care
system is considered as one of the most expensive healthcare system in the
world, spending about 16% of its GDP on healthcare. However the rising
healthcare costs and increasing health premiums rates along with high number
of uninsured people (about 47 million i.e. 16% of the total population) are
among the significant factors contributing to the need of health reform in
the US. Health reform in the US is looked upon as an initiative towards
provision of qualitative and affordable health coverage for all Americans,
decrease in rising burden of healthcare costs and improvement in quality &
efficiency of health care. Obama has signed health reform in to law, recently
in March 2010, to improve the inefficiencies of the existing health care
structure. The health reform bill outlays several provisions such as
universal health coverage, cost containment, increase in insurance market
competition, excise tax on medical device manufacturers and lower drug costs
for Medicaid and Medicare are few to mention. Thus the provisions in the
health reform directly and indirectly impact the US healthcare/pharmaceutical
industry and its stakeholders.

SCOPE AND FORMAT

The report will enable understanding of following key areas related to
Obama's health reform

    - Obama's Health reform bills (Patient Protection and
      Affordable Care Act and Health Care and Education Reconciliation Act on
      2010) and other health initiatives (Children's Health Insurance
      Reauthorization and American Recovery and Reinvestment Act)
    - Impact of Obama's health reforms provisions on the US
      healthcare/pharmaceutical industry
    - Impact of Obama's health reforms on the several healthcare
      industry stakeholders (payers, providers and consumers) and medical
      devices, biotech & pharmaceutical drug manufacturers and suppliers

Stake holders

    - Companies such as medical devices, drug and devices R&D,
      pharmaceutical and biotech
    - Healthcare service providers such as hospitals, medical centers
      and medical associations.
    - Health Coverage providers such as employers and private health
      providers

INFORMATION SOURCES

Each of the section will provide market data, key findings and strategic
analysis related to US healthcare structure or Obama's health reforms. In
addition the report also provides impact analysis of Obama's health reform on
the US healthcare industry from different prospective such as impact on
healthcare industry stakeholders, drug & medical device manufacturers and
impact analysis of several provisions of health reforms on
healthcare/pharmaceutical industry. Secondary research will progress through
both paid and unpaid sources. We will conduct primary research to provide
in-depth understanding of the healthcare structure in the US and impact of
Obama's health reforms on the healthcare/pharmaceutical industry.

       Table of Contents

    1. Introduction
    1.1. Key Take Away
    1.2. Report Description
    1.3. Stakeholders
    1.4. Research Methodology

    2. Summary

    3. Market Overview
    3.1. Overview of Health Care System in the US
    3.2. Healthcare reforms in the United States
        3.2.1. Agenda of Obama's health reform
        3.2.2. Analysis of Benefits and challenges of Obama's health reform
        3.2.3. Impact of Obama's health reform on the US
               healthcare/pharmaceutical industry
    3.3. Debate on Obama's health reform

    4. US Healthcare system Overview
    4.1. Healthcare Structure
        4.1.1. Reimbursement and financing
        4.1.1.1. Public healthcare insurance
        4.1.1.2. Private health coverage
    4.1.2. Regulatory environment
        4.1.2.1. Health Care Laws
        4.1.2.2. Regulating Bodies
            4.1.2.2.1. The Center for Devices and Radiological Health (CDRH)
            4.1.2.2.2. US Food and Drug Administration (FDA)
    4.2. Healthcare Expenditure
        4.2.1. Total Healthcare expenditure
        4.2.2. Per capita healthcare expenditure
        4.2.3. Health care budget and health reform
        4.2.4. Obama's Stimulus Package for health sector
    4.3. Issues with the US healthcare system / Need of the health reform
        4.3.1. Rising Healthcare Costs
        4.3.2. Unaffordable health insurance
        4.3.3 Uneven health coverage
        4.3.4. Others

    5. Obama's Health Reform
    5.1. Obama's proposed strategies for health reform prior to health reform
         bill formation 5.1.1. Expansion of public health coverage
        5.1.2. Changes in private health coverage
        5.1.3. Premium subsidies to individual and employers
        5.1.4. Tax Reform
        5.1.5. Others
    5.2. Obama's initiatives in health care
        5.2.1. Obama's health reform
            5.2.1.1. Key elements of Obama's health reform
            5.2.1.1.1. Affordable healthcare
            5.2.1.1.2. Improvement in quality and efficiency of healthcare
            5.2.1.1.3. Prevention of chronic diseases
            5.2.1.1.4. Wider health coverage
            5.2.1.1.5. Others
        5.2.1.2. Health reform Bills
            5.2.1.2.1. Patient Protection and Affordable Care Act
            5.2.1.2.2. Health Care and Education Reconciliation Act on 2010
        5.2.1.3. Key differentiating factors
        5.2.1.4. Health Reform Implementation Timeline
    5.2.2. Other health initiatives
        5.2.2.1. Children's Health Insurance Reauthorization
        5.2.2.2. American Recovery and Reinvestment Act

    6. Impact of Obama's health reform provisions on the US
       healthcare/pharmaceutical industry
    6.1. Insurance market reforms
    6.2. Reducing premiums for affordable Coverage
    6.3. Small employer tax credit
    6.4. Affordable Choices for small businesses
    6.5. Cost Containment
    6.6. Health Insurance Exchange
    6.7. Improvement in Medicaid
    6.8. Decrease in Waste, Fraud and Abuse
    6.9. Biologics Price Competition and Innovation Act
    6.10. Others
    6.11. Impact of Health Reforms on healthcare industry stakeholders
        6.11.1. Providers
            6.11.1.1. Hospitals
            6.11.1.2. Physicians
        6.11.2. Payers
            6.11.2.1. Public insurance
            6.11.2.2. Private coverage
        6.11.3. Consumers / Beneficiaries
            6.11.3.1. Families
            6.11.3.2. Seniors
            6.11.3.3. Women
            6.11.3.4. Racial and Ethnic minorities
            6.11.3.5. Rural population
            6.11.3.6. Children
            6.11.3.7. Others
    6.12. Impact of Health Reforms on healthcare/ pharmaceutical market
        6.12.1. Medical devices/equipment manufacturers and suppliers
            6.12.1.1. Excise Tax
            6.12.1.2. Increase in business cost and competition
            6.12.1.3. Competitive bidding programs for suppliers
            6.12.1.4. Accelerate new platform technologies
            6.12.1.5. Others
        6.12.2. Pharma and Biotech Drug manufacturers
            6.12.2.1. Lower drug prices through Medicaid and Medicare
            6.12.2.2. Rebates for new formulations of brand name drugs
            6.12.2.3. Increase inspection and compliance costs
            6.12.2.4. New approval regulatory pathway for biosimilars
            6.12.2.5. Approval of generic drugs
            6.12.2.6. Others

    7. Conclusion on Obama's health reform
    7.1. Economic Impact of Obama's health reform
    7.2. Brief on holistic impact analysis of Obama's health reform on the US
         healthcare system

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting
company based in the U.S. We publish strategically analyzed market research
reports and serve as a business intelligence partner to Fortune 500 companies
across the world. MarketsandMarkets also provides multi-client reports,
company profiles, databases, and custom research services.

M&M covers thirteen industry verticals, including advanced materials,
automotive and transportation, banking and financial services, biotechnology,
chemicals, consumer goods energy and power, food and beverages, industrial
automation, medical devices, pharmaceuticals, semiconductor and electronics,
and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by
providing apt business insight with our huge market intelligence repository.
To know more about us and our reports, please visit our website
www.marketsandmarkets.com

    Contact:
    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    Email: sales@marketsandmarkets.com
    www.marketsandmarkets.com

Contact: Ms. Sunita, 7557 Rambler road, Suite 727, Dallas, TX 75231, Tel: +1-888-989-8004, Email: sales at marketsandmarkets.com